Published in J Invest Dermatol on November 19, 2009
Comparison of different assays to assess human papillomavirus (HPV) type 16- and 18-specific antibodies after HPV infection and vaccination. Clin Vaccine Immunol (2013) 0.90
Human papillomaviruses: shared and distinct pathways for pathogenesis. Curr Opin Virol (2015) 0.82
Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med (2007) 16.39
Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study. J Natl Cancer Inst (2003) 6.28
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis (2009) 5.09
A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. Int J Cancer (2007) 4.29
Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst (2010) 4.20
Multiplex human papillomavirus serology based on in situ-purified glutathione s-transferase fusion proteins. Clin Chem (2005) 4.18
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis (2009) 3.55
Bead-based multiplex genotyping of human papillomaviruses. J Clin Microbiol (2006) 3.13
Suppression of non-specific binding in serological Luminex assays. J Immunol Methods (2005) 2.96
Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med (2011) 2.93
Evaluation of human papillomavirus antibodies and risk of subsequent head and neck cancer. J Clin Oncol (2013) 2.87
A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila) (2009) 2.42
Human papillomavirus infection and incidence of squamous cell and basal cell carcinomas of the skin. J Natl Cancer Inst (2006) 2.40
HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine (2008) 2.09
The human cytomegalovirus. Pharmacol Ther (2003) 2.06
Helicobacter pylori protein-specific antibodies and risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev (2013) 2.01
HPV antibody detection by ELISA with capsid protein L1 fused to glutathione S-transferase. J Virol Methods (2002) 1.97
Human papillomavirus-DNA loads in actinic keratoses exceed those in non-melanoma skin cancers. J Invest Dermatol (2005) 1.94
Homogeneous amplification of genital human alpha papillomaviruses by PCR using novel broad-spectrum GP5+ and GP6+ primers. J Clin Microbiol (2008) 1.90
Mutations in two adjacent novel genes are associated with epidermodysplasia verruciformis. Nat Genet (2002) 1.90
Large scale genotype comparison of human papillomavirus E2-host interaction networks provides new insights for e2 molecular functions. PLoS Pathog (2012) 1.79
Biomarkers of HPV in head and neck squamous cell carcinoma. Cancer Res (2012) 1.76
The human papillomavirus type 8 E2 protein induces skin tumors in transgenic mice. J Invest Dermatol (2008) 1.71
Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Hum Vaccin (2009) 1.66
The intracellular DNA sensor IFI16 gene acts as restriction factor for human cytomegalovirus replication. PLoS Pathog (2012) 1.64
High-risk HPV types and head and neck cancer. Int J Cancer (2014) 1.56
Evaluation of antibodies to human papillomavirus as prognostic markers in cervical cancer patients. Gynecol Oncol (2002) 1.56
Low human papillomavirus prevalence in head and neck cancer: results from two large case-control studies in high-incidence regions. Int J Epidemiol (2011) 1.55
Abundance of multiple high-risk human papillomavirus (HPV) infections found in cervical cells analyzed by use of an ultrasensitive HPV genotyping assay. J Clin Microbiol (2009) 1.55
Primary HIV drug resistance and efficacy of first-line antiretroviral therapy guided by resistance testing. J Acquir Immune Defic Syndr (2006) 1.53
Human papillomavirus-16 is the predominant type etiologically involved in penile squamous cell carcinoma. J Clin Oncol (2007) 1.53
Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination. Clin Cancer Res (2004) 1.51
Viral RNA patterns and high viral load reliably define oropharynx carcinomas with active HPV16 involvement. Cancer Res (2012) 1.49
High-throughput detection and multiplex identification of cell contaminations. Nucleic Acids Res (2009) 1.49
Risk factors for anal cancer in persons infected with HIV: a nested case-control study in the Swiss HIV Cohort Study. Am J Epidemiol (2013) 1.48
High-throughput SNP-based authentication of human cell lines. Int J Cancer (2012) 1.46
Merkel cell polyomavirus DNA in persons without merkel cell carcinoma. Emerg Infect Dis (2009) 1.45
Serologic response to oncogenic human papillomavirus types in male and female university students in Busan, South Korea. Cancer Epidemiol Biomarkers Prev (2007) 1.45
Neuromyelitis optica following human papillomavirus vaccination. Neurology (2012) 1.44
Seroprevalence of 34 human papillomavirus types in the German general population. PLoS Pathog (2008) 1.44
Benchmarking a luciferase complementation assay for detecting protein complexes. Nat Methods (2011) 1.44
Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva. Eur J Cancer (2013) 1.42
Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide. Int J Cancer (2014) 1.40
[Comment. HPV7-induced skin warts in butchers: an occupational disease?]. J Dtsch Dermatol Ges (2003) 1.40
Human papillomavirus seropositivity and risks of head and neck cancer. Int J Cancer (2007) 1.39
Compensatory mutations at the HIV cleavage sites p7/p1 and p1/p6-gag in therapy-naive and therapy-experienced patients. Antivir Ther (2006) 1.37
Reactivity pattern of 92 monoclonal antibodies with 15 human papillomavirus types. J Gen Virol (2008) 1.35
Development of skin tumors in mice transgenic for early genes of human papillomavirus type 8. Cancer Res (2005) 1.34
Helicobacter pylori infection and gastric cancer risk: evaluation of 15 H. pylori proteins determined by novel multiplex serology. Cancer Res (2009) 1.33
Evolution of raltegravir resistance during therapy. J Antimicrob Chemother (2009) 1.33
Regulation of cellular zinc balance as a potential mechanism of EVER-mediated protection against pathogenesis by cutaneous oncogenic human papillomaviruses. J Exp Med (2007) 1.33
High prevalence of epidermodysplasia verruciformis-associated human papillomavirus DNA in actinic keratoses of the immunocompetent population. Arch Dermatol Res (2003) 1.32
Multicenter study of the association between betapapillomavirus infection and cutaneous squamous cell carcinoma. Cancer Res (2010) 1.30
Human papillomavirus infection in Ulaanbaatar, Mongolia: a population-based study. Cancer Epidemiol Biomarkers Prev (2008) 1.29
Human papillomavirus infections and upper aero-digestive tract cancers: the ARCAGE study. J Natl Cancer Inst (2013) 1.29
Helicobacter pylori multiplex serology. Helicobacter (2009) 1.29
Complex etiology underlies risk and survival in head and neck cancer human papillomavirus, tobacco, and alcohol: a case for multifactor disease. J Oncol (2012) 1.27
Race, African ancestry, and Helicobacter pylori infection in a low-income United States population. Cancer Epidemiol Biomarkers Prev (2011) 1.26
Human papillomavirus type 16 and TP53 mutation in oral cancer: matched analysis of the IARC multicenter study. Cancer Res (2004) 1.25
Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins. Cancer Res (2003) 1.24
Pathogenic role of the eight probably/possibly carcinogenic HPV types 26, 53, 66, 67, 68, 70, 73 and 82 in cervical cancer. J Pathol (2014) 1.23
A novel role of the interferon-inducible protein IFI16 as inducer of proinflammatory molecules in endothelial cells. J Biol Chem (2007) 1.23
A prospective pilot study of antibodies against human papillomaviruses and cutaneous squamous cell carcinoma nested in the Oxford component of the European Prospective Investigation into Cancer and Nutrition. Int J Cancer (2007) 1.22
Versatile biosynthetic engineering of sialic acid in living cells using synthetic sialic acid analogues. J Biol Chem (2001) 1.22
The high-mobility-group box protein SSRP1/T160 is essential for cell viability in day 3.5 mouse embryos. Mol Cell Biol (2003) 1.21
Role of the interferon-inducible gene IFI16 in the etiopathogenesis of systemic autoimmune disorders. Ann N Y Acad Sci (2007) 1.21
Genus beta human papillomaviruses and incidence of basal cell and squamous cell carcinomas of skin: population based case-control study. BMJ (2010) 1.18
Interaction between inflammation and angiogenesis during different stages of cervical carcinogenesis. Gynecol Oncol (2007) 1.18
Prevalence and stability of antibodies to the BK and JC polyomaviruses: a long-term longitudinal study of Australians. J Gen Virol (2010) 1.16
Global hypomethylation identifies Loci targeted for hypermethylation in head and neck cancer. Clin Cancer Res (2011) 1.15
Genomic organization of amplified MYC genes suggests distinct mechanisms of amplification in tumorigenesis. Cancer Res (2005) 1.14
T25 repeat in the 3' untranslated region of the CASP2 gene: a sensitive and specific marker for microsatellite instability in colorectal cancer. Cancer Res (2005) 1.13
Prospective study of Helicobacter pylori biomarkers for gastric cancer risk among Chinese men. Cancer Epidemiol Biomarkers Prev (2012) 1.13
Spontaneous tumour development in human papillomavirus type 8 E6 transgenic mice and rapid induction by UV-light exposure and wounding. J Gen Virol (2009) 1.13
Risk factors and survival by HPV-16 E6 and E7 antibody status in human papillomavirus positive head and neck cancer. Int J Cancer (2010) 1.12
Seroreactivity to cutaneous human papillomaviruses among patients with nonmelanoma skin cancer or benign skin lesions. Cancer Epidemiol Biomarkers Prev (2008) 1.12
Human papillomavirus type 16 L1 capsomeres induce L1-specific cytotoxic T lymphocytes and tumor regression in C57BL/6 mice. J Virol (2003) 1.12